Literature DB >> 17661048

Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis.

Kaori Iwai1, Masaru Ishii, Shiro Ohshima, Kunio Miyatake, Yukihiko Saeki.   

Abstract

Tetraspanin CD9 has been shown to be critically involved in multinucleation and cell fusion during osteoclastogenesis, however, its in vivo pathophysiological role in bone-resorbing disorders such as osteoporosis and rheumatoid arthritis, has not been elucidated. To investigate the involvement of tetraspanin CD9 in bone destruction in such diseases, we examined the expression and distribution of tetraspanin CD9 using murine experimental models of osteoporosis and arthritis. In results, CD9 protein is abundantly expressed on the activated osteoclasts in the bone tissues whose trabeculae are severely reduced in ovariectomy-induced osteoporosis. The expression of CD9 is also detected at the sites of bone erosion in arthritic lesions of collagen-induced arthritis (CIA), where tartate-resistant acid phosphatase (TRAP) staining-positive activated osteoclasts are present. These data suggest that tetraspanin CD9 play important roles in bone destructions in osteoporosis and arthritis, and therefore, functional alterations of tetraspanin CD9 may have therapeutic potential in such bone-resorptive disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17661048     DOI: 10.1007/s00296-007-0424-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  34 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

Review 2.  Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women.

Authors:  Cristiano Maria Francucci; Andrea Camilletti; Marco Boscaro
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

Review 3.  Anti-cytokine therapy for rheumatoid arthritis.

Authors:  R N Maini; P C Taylor
Journal:  Annu Rev Med       Date:  2000       Impact factor: 13.739

4.  Early menopausal changes in bone mass and sex steroids.

Authors:  C C Johnston; S L Hui; R M Witt; R Appledorn; R S Baker; C Longcope
Journal:  J Clin Endocrinol Metab       Date:  1985-11       Impact factor: 5.958

Review 5.  RANKL-RANK signaling in osteoclastogenesis and bone disease.

Authors:  Teiji Wada; Tomoki Nakashima; Nishina Hiroshi; Josef M Penninger
Journal:  Trends Mol Med       Date:  2005-12-13       Impact factor: 11.951

Review 6.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

7.  Bidirectional erosion of cartilage in the rheumatoid knee joint.

Authors:  M Bromley; H Bertfield; J M Evanson; D E Woolley
Journal:  Ann Rheum Dis       Date:  1985-10       Impact factor: 19.103

Review 8.  Inhibition of IL-6 for the treatment of inflammatory diseases.

Authors:  Norihiro Nishimoto; Tadamitsu Kishimoto
Journal:  Curr Opin Pharmacol       Date:  2004-08       Impact factor: 5.547

9.  Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice.

Authors:  J M Stuart; A S Townes; A H Kang
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

10.  Autoimmunity to type II collagen an experimental model of arthritis.

Authors:  D E Trentham; A S Townes; A H Kang
Journal:  J Exp Med       Date:  1977-09-01       Impact factor: 14.307

View more
  4 in total

1.  CD9 induces cellular senescence and aggravates atherosclerotic plaque formation.

Authors:  Jung Hee Cho; Eok-Cheon Kim; Youlim Son; Da-Woon Lee; Yong Seop Park; Joon Hyuk Choi; Kyung-Hyun Cho; Ki-Sun Kwon; Jae-Ryong Kim
Journal:  Cell Death Differ       Date:  2020-04-28       Impact factor: 15.828

2.  OC-STAMP promotes osteoclast fusion for pathogenic bone resorption in periodontitis via up-regulation of permissive fusogen CD9.

Authors:  Takenobu Ishii; Montserrat Ruiz-Torruella; Atsushi Ikeda; Satoru Shindo; Alexandru Movila; Hani Mawardi; Abdullah Albassam; Rayyan A Kayal; Ayman A Al-Dharrab; Kenji Egashira; Wichaya Wisitrasameewong; Kenta Yamamoto; Abdulghani I Mira; Kenji Sueishi; Xiaozhe Han; Martin A Taubman; Takeshi Miyamoto; Toshihisa Kawai
Journal:  FASEB J       Date:  2018-03-13       Impact factor: 5.191

3.  Osteoclast fusion and regulation by RANKL-dependent and independent factors.

Authors:  Lianping Xing; Yan Xiu; Brendan F Boyce
Journal:  World J Orthop       Date:  2012-12-18

4.  Atorvastatin inhibits osteoclast differentiation by suppressing NF-κB and MAPK signaling during IL-1β-induced osteoclastogenesis.

Authors:  Won-Seok Lee; Eun-Gyeong Lee; Myung-Soon Sung; Yun-Jung Choi; Wan-Hee Yoo
Journal:  Korean J Intern Med       Date:  2017-03-28       Impact factor: 2.884

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.